Research-based PAM50 signature and long-term breast cancer survival

被引：0
|
作者：
Minya Pu
Karen Messer
Sherri R. Davies
Tammi L. Vickery
Emily Pittman
Barbara A. Parker
Matthew J. Ellis
Shirley W. Flatt
Catherine R. Marinac
Sandahl H. Nelson
Elaine R. Mardis
John P. Pierce
Loki Natarajan
机构：
[1] University of California,Moores Cancer Center
[2] San Diego,Department of Family Medicine and Public Health
[3] University of California,Department of Medicine
[4] San Diego,Department of Medicine
[5] Washington University St. Louis,Baylor College of Medicine
[6] Washington University St. Louis,Division of Population Sciences, Department of Medical Oncology
[7] McDonnell Genome Institute,Department of Epidemiology
[8] University of California,undefined
[9] San Diego,undefined
[10] Lester and Sue Smith Breast Center,undefined
[11] Nationwide Children’s Hospital,undefined
[12] Institute for Genomic Medicine,undefined
[13] Dana-Farber Cancer Institute,undefined
[14] Harvard T.H. Chan School of Public Health,undefined
[15] Precision for Medicine,undefined
来源：
Breast Cancer Research and Treatment | 2020年 / 179卷
关键词：
Breast cancer; Long-term survival; Gene signatures; Hypoxia; PAM50 subtypes; Prognostic modeling;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：197 / 206
页数：9
相关论文
共 50 条
  • [21] Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
    Ohnstad, Hege O.
    Borgen, Elin
    Falk, Ragnhild S.
    Lien, Tonje G.
    Aaserud, Marit
    Sveli, My Anh T.
    Kyte, Jon A.
    Kristensen, Vessela N.
    Geitvik, Gry A.
    Schlichting, Ellen
    Wist, Erik A.
    Sorlie, Therese
    Russnes, Hege G.
    Naume, Bjorn
    BREAST CANCER RESEARCH, 2017, 19
  • [22] Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up
    Hege O. Ohnstad
    Elin Borgen
    Ragnhild S. Falk
    Tonje G. Lien
    Marit Aaserud
    My Anh T. Sveli
    Jon A. Kyte
    Vessela N. Kristensen
    Gry A. Geitvik
    Ellen Schlichting
    Erik A. Wist
    Therese Sørlie
    Hege G. Russnes
    Bjørn Naume
    Breast Cancer Research, 19
  • [23] Intrinsic Subtypes from the PAM50 Gene Expression Assay in a Population-Based Breast Cancer Survivor Cohort: Prognostication of Short- and Long-term Outcomes
    Caan, Bette J.
    Sweeney, Carol
    Habel, Laurel A.
    Kwan, Marilyn L.
    Kroenke, Candyce H.
    Weltzien, Erin K.
    Quesenberry, Charles P., Jr.
    Castillo, Adrienne
    Factor, Rachel E.
    Kushi, Lawrence H.
    Bernard, Philip S.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (05) : 725 - 734
  • [24] Body Mass Index, PAM50 Subtype, Recurrence, and Survival Among Patients With Nonmetastatic Breast Cancer
    Feliciano, Elizabeth M. Cespedes
    Kwan, Marilyn L.
    Kushi, Lawrence H.
    Chen, Wendy Y.
    Weltzien, Erin K.
    Castillo, Adrienne L.
    Sweeney, Carol
    Bernard, Philip S.
    Caan, Bette J.
    CANCER, 2017, 123 (13) : 2535 - 2542
  • [25] Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study
    Troester, Melissa A.
    Sun, Xuezheng
    Allott, Emma H.
    Geradts, Joseph
    Cohen, Stephanie M.
    Tse, Chiu-Kit
    Kirk, Erin L.
    Thorne, Leigh B.
    Mathews, Michelle
    Li, Yan
    Hu, Zhiyuan
    Robinson, Whitney R.
    Hoadley, Katherine A.
    Olopade, Olufunmilayo I.
    Reeder-Hayes, Katherine E.
    Earp, H. Shelton
    Olshan, Andrew F.
    Carey, Lisa A.
    Perou, Charles M.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (02):
  • [26] Comparison of the pam50 intrinsic subtypes with immunohistochemistry in breast cancer patients
    Honrado, E.
    Saez Alvarez, S.
    Lopez Gonzalez, A.
    Tavara Silva, B. I.
    Prieto Dominguez, L.
    Martinez Martinez, J.
    Lopez Flores, M. A.
    Garcia Palomo, A.
    VIRCHOWS ARCHIV, 2020, 477 : S47 - S47
  • [27] PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients
    Jorgensen, Charlotte L. T.
    Nielsen, Torsten O.
    Bjerre, Karsten D.
    Liu, Shuzhen
    Wallden, Brett
    Balslev, Eva
    Nielsen, Dorte L.
    Ejlertsen, Bent
    ACTA ONCOLOGICA, 2014, 53 (06) : 776 - 787
  • [28] Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies
    Bianchini, G.
    Parker, J.
    Carey, L.
    Perou, C. M.
    Sica, L.
    Prat, A.
    Pienkowski, T.
    Im, Y-H.
    Bianchi, G. V.
    Ling-Ming, T.
    Liu, M-C.
    Lluch, A.
    Semiglazov, V.
    de la Haba-Rodriguez, J.
    Oh, D-Y.
    Poirier, B.
    Pedrini, J. L.
    Valagussa, P.
    Gianni, L.
    ANNALS OF ONCOLOGY, 2018, 29 : 61 - 61
  • [29] PAM50 breast cancer subtyping and risk of recurrence in a population-based cohort.
    Bernard, Philip
    Weltzien, Erin
    Stijleman, Inge
    Kroenke, Candyce H.
    Davis, Carole
    Kwan, Marilyn L.
    Quesenberry, Charles
    Castillo, Adrienne
    Habel, Laurel
    Factor, Rachel
    Kushi, Larry
    Sweeney, Carol
    Caan, Bette
    CANCER RESEARCH, 2013, 73 (08)
  • [30] Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer
    Srinivas Veerla
    Lennart Hohmann
    Deborah F. Nacer
    Johan Vallon-Christersson
    Johan Staaf
    npj Breast Cancer, 9
12345